BRPI0810322A2 - "CÉLULA EBx DE AVE TRANSFECTADA, MÉTODO DE PRODUÇÃO DE PELO MENOS UM PRODUTO BIOLÓGICO DE INTERESSE, PRODUTO BIOLÓGICO DE INTERESSE, POPULAÇÃO DE ANTICORPO, ANTICORPOS, USOS DE UM PRODUTO BIOLÓGICO E DE UM ANTICORPO OU UM FRAGMENTO DESTE E COMPOSIÇÃO FARMACÊUTICA" - Google Patents

"CÉLULA EBx DE AVE TRANSFECTADA, MÉTODO DE PRODUÇÃO DE PELO MENOS UM PRODUTO BIOLÓGICO DE INTERESSE, PRODUTO BIOLÓGICO DE INTERESSE, POPULAÇÃO DE ANTICORPO, ANTICORPOS, USOS DE UM PRODUTO BIOLÓGICO E DE UM ANTICORPO OU UM FRAGMENTO DESTE E COMPOSIÇÃO FARMACÊUTICA"

Info

Publication number
BRPI0810322A2
BRPI0810322A2 BRPI0810322-4A2A BRPI0810322A BRPI0810322A2 BR PI0810322 A2 BRPI0810322 A2 BR PI0810322A2 BR PI0810322 A BRPI0810322 A BR PI0810322A BR PI0810322 A2 BRPI0810322 A2 BR PI0810322A2
Authority
BR
Brazil
Prior art keywords
biological product
interest
antibody
ave
antibodies
Prior art date
Application number
BRPI0810322-4A2A
Other languages
English (en)
Inventor
Majid Mehtali
Original Assignee
Vivalis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivalis filed Critical Vivalis
Publication of BRPI0810322A2 publication Critical patent/BRPI0810322A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
BRPI0810322-4A2A 2007-05-21 2008-05-21 "CÉLULA EBx DE AVE TRANSFECTADA, MÉTODO DE PRODUÇÃO DE PELO MENOS UM PRODUTO BIOLÓGICO DE INTERESSE, PRODUTO BIOLÓGICO DE INTERESSE, POPULAÇÃO DE ANTICORPO, ANTICORPOS, USOS DE UM PRODUTO BIOLÓGICO E DE UM ANTICORPO OU UM FRAGMENTO DESTE E COMPOSIÇÃO FARMACÊUTICA" BRPI0810322A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301058A EP1995309A1 (en) 2007-05-21 2007-05-21 Recombinant protein production in avian EBx® cells
US3278608P 2008-02-29 2008-02-29
PCT/EP2008/056285 WO2008142124A1 (en) 2007-05-21 2008-05-21 Recombinant protein production in avian ebx® cells

Publications (1)

Publication Number Publication Date
BRPI0810322A2 true BRPI0810322A2 (pt) 2014-10-14

Family

ID=38521438

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810322-4A2A BRPI0810322A2 (pt) 2007-05-21 2008-05-21 "CÉLULA EBx DE AVE TRANSFECTADA, MÉTODO DE PRODUÇÃO DE PELO MENOS UM PRODUTO BIOLÓGICO DE INTERESSE, PRODUTO BIOLÓGICO DE INTERESSE, POPULAÇÃO DE ANTICORPO, ANTICORPOS, USOS DE UM PRODUTO BIOLÓGICO E DE UM ANTICORPO OU UM FRAGMENTO DESTE E COMPOSIÇÃO FARMACÊUTICA"

Country Status (15)

Country Link
US (1) US20100226912A1 (pt)
EP (2) EP1995309A1 (pt)
JP (1) JP2010529833A (pt)
KR (1) KR20100016540A (pt)
CN (1) CN101688179A (pt)
AU (1) AU2008252902B2 (pt)
BR (1) BRPI0810322A2 (pt)
CA (1) CA2687493A1 (pt)
EA (1) EA017964B1 (pt)
IL (1) IL202213A0 (pt)
MX (1) MX2009012747A (pt)
MY (1) MY159013A (pt)
NZ (1) NZ580820A (pt)
WO (1) WO2008142124A1 (pt)
ZA (1) ZA200908195B (pt)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539045T3 (es) 2009-01-19 2015-06-25 Innate Pharma Anticuerpos anti-KIR3D
US8815242B2 (en) 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
WO2011015918A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant cetuximab
WO2011015924A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant trastuzumab
WO2011040526A1 (ja) * 2009-09-30 2011-04-07 国立大学法人帯広畜産大学 α-ガラクトースエピトープ発現ウイルス及びワクチンの作製方法
EP2531592A1 (en) 2010-02-04 2012-12-12 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
EP2374816B1 (en) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
WO2011124635A1 (en) 2010-04-07 2011-10-13 Humalys Binding molecules against chikungunya virus and uses thereof
EP2603526A1 (en) 2010-08-13 2013-06-19 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
WO2012095514A1 (en) * 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
AU2012327878A1 (en) 2011-10-28 2014-05-29 Patrys Limited PAT-LM1 epitopes and methods for using same
ES2749349T3 (es) 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
HRP20200744T1 (hr) * 2011-12-22 2020-07-24 F. Hoffmann - La Roche Ag Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida
RU2756910C2 (ru) * 2011-12-22 2021-10-06 Ф. Хоффманн-Ля Рош Аг Комбинации элементов экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
WO2013117647A1 (en) 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
KR20140015999A (ko) * 2012-07-27 2014-02-07 한화케미칼 주식회사 신규 ＭＡＲｓ 및 이를 이용하여 목적 단백질을 생산하는 방법
US20160194660A1 (en) * 2012-12-21 2016-07-07 Merck Sharp & Dohme Corp. Expression vectors for recombinant protein production in mammalian cells
PT2951208T (pt) 2013-02-01 2019-12-30 Univ California Anticorpos anti-cd83 e sua utilização
KR102489953B1 (ko) 2013-02-07 2023-01-20 씨에스엘 리미티드 Il-11r 결합 단백질 및 이의 용도
US9534041B2 (en) 2013-02-12 2017-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that neutralize a norovirus
EP2956482B1 (en) 2013-02-14 2017-06-28 Innate Pharma Treatment of peripheral t cell lymphoma
DK2958941T3 (da) 2013-02-20 2019-06-24 Innate Pharma Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
US9101597B2 (en) * 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
EP3583950A1 (en) 2013-05-09 2019-12-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
PT3052192T (pt) 2013-10-02 2020-09-24 Medimmune Llc Anticorpos neutralizantes anti-influenza a e suas utilizações
KR101591823B1 (ko) * 2013-12-27 2016-02-04 재단법인 목암생명공학연구소 증가된 유전자 발현능을 갖는 발현벡터
BR112016017817A2 (pt) 2014-02-06 2017-10-10 Genzyme Corp composições e métodos para o tratamento e a prevenção de degeneração macular
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
CA2954780A1 (en) 2014-07-15 2016-01-21 Medimmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
WO2016030488A1 (en) 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
CA2963166C (en) 2014-10-01 2023-10-03 Medimmune Limited Antibodies to ticagrelor and methods of use
CN104531699B (zh) * 2014-10-09 2017-03-15 河南农业大学 一种增强外源基因表达的猪的ucoe调控元件片段
US10870704B2 (en) 2014-10-23 2020-12-22 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
WO2016061632A1 (en) 2014-10-23 2016-04-28 La Trobe University Fn14-binding proteins and uses thereof
WO2016090170A1 (en) 2014-12-05 2016-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A potent anti-influenza a neuraminidase subtype n1 antibody
ES2784264T3 (es) 2014-12-17 2020-09-23 Fundacion Para La Investig Medica Aplicada Construcciones de ácido nucleico y vectores de terapia génica para su uso en el tratamiento de la enfermedad de Wilson y otras afecciones
JP6865167B2 (ja) 2014-12-17 2021-04-28 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ウィルソン病の処置に使用するための核酸構築物及び遺伝子治療ベクター
JP7095994B2 (ja) 2015-03-02 2022-07-05 アドヴェラム バイオテクノロジーズ， インコーポレイテッド ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法
EP3960761A1 (en) 2015-06-01 2022-03-02 MedImmune, LLC Neutralizing anti-influenza binding molecules and uses thereof
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
BR112018068678A2 (pt) 2016-03-15 2019-01-15 Innate Pharma anticorpos anti-mica
CL2016001661A1 (es) * 2016-06-29 2017-03-03 Univ Chile Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes.
EP3504237A1 (en) 2016-08-23 2019-07-03 Medimmune Limited Anti-vegf-a and anti-ang2 antibodies and uses thereof
JP6949106B2 (ja) 2016-08-23 2021-10-13 メディミューン リミテッド 抗ｖｅｇｆ−ａ抗体ならびにそれらの使用
CN109863175A (zh) 2016-10-21 2019-06-07 依奈特制药公司 用抗-kir3dl2药剂进行的治疗
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
JP7733443B2 (ja) 2017-09-11 2025-09-03 モナシュ ユニバーシティー ヒトトロンビン受容体ｐａｒ４に対する結合タンパク質
JP7401432B2 (ja) 2017-12-01 2023-12-19 エンコーデッド セラピューティクス， インコーポレイテッド 操作されたｄｎａ結合タンパク質
CN108300704B (zh) * 2018-02-08 2022-04-05 华农（肇庆）生物产业技术研究院有限公司 一种用传代细胞系悬浮培养传染性支气管炎病毒的方法
US20210180084A1 (en) 2018-05-14 2021-06-17 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
WO2020034097A1 (en) * 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
FI3852617T3 (fi) 2018-09-20 2025-10-21 Sfj Pharma X Inc Vasta-ainefragmenttien käyttö tikagrelorin aktiivisuuden kääntämiseen
CA3116098A1 (en) 2018-10-12 2020-04-16 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
JP2022512930A (ja) 2018-11-07 2022-02-07 ヴィヴェ テラピューティクス 進行性家族性肝内胆汁鬱滞タイプ２（ｐｆｉｃ２）の治療のためのコドン最適化ａｂｃｂ１１導入遺伝子
EP3880809A4 (en) 2018-11-16 2023-01-11 Encoded Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF WILSON'S DISEASE
EP3884039A1 (en) * 2018-11-23 2021-09-29 Valneva SE Food products comprising avian stem cells
WO2020243651A1 (en) 2019-05-29 2020-12-03 Encoded Therapeutics, Inc. Compositions and methods for selective gene regulation
CN110484546B (zh) * 2019-06-24 2021-05-14 四川农业大学 一种3型鸭甲肝病毒突变基因isa-c4334a及构建方法
CA3145446A1 (en) 2019-07-02 2021-01-07 Fundacion Para La Investigacion Medica Aplicada Cpla2e inducing agents and uses thereof
EP3914720B9 (en) 2019-07-10 2023-09-27 Masonic Medical Research Laboratory Vgll4 with ucp-1 cis-regulatory element and method of use thereof
TW202214864A (zh) 2020-08-06 2022-04-16 應用醫學研究基金會 用於藉基因療法治療諸如阿茲海默症之Ｔａｕ蛋白病變的病毒顆粒
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
US20220098617A1 (en) * 2020-09-29 2022-03-31 NeuExcell Therapeutics Inc. Ascl1 vector
MX2023003656A (es) * 2020-09-29 2023-06-22 Neuexcell Therapeutics Inc Vector dlx2.
EP4222270A4 (en) * 2020-09-29 2025-02-26 Neuexcell Therapeutics Inc. NEUROD1-VECTOR
WO2022072324A1 (en) * 2020-09-29 2022-04-07 NeuExcell Therapeutics Inc. Isl1 and lhx3 vector
MX2023003654A (es) * 2020-09-29 2023-06-22 Neuexcell Therapeutics Inc Vector de combinación de neurod1.
PH12023550860A1 (en) * 2020-09-29 2023-11-20 Neuexcell Therapeutics Inc Neurod1 and dlx2 vector
CN116390935A (zh) 2020-10-09 2023-07-04 Ucb生物制药有限责任公司 核酸构建体、病毒载体和病毒颗粒
WO2022136616A1 (en) 2020-12-23 2022-06-30 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2
CN113215097B (zh) * 2021-06-24 2023-03-24 成都中医药大学 一种高比例b7h4阳性脐带间充质干细胞、其培养方法及培养液
JP2024543001A (ja) 2021-10-28 2024-11-19 ユーシービー バイオファルマ エスアールエル 核酸構築物、ウイルスベクターおよびウイルス粒子
WO2025184493A1 (en) * 2024-02-29 2025-09-04 Amgen Inc. Dual selection expression vector systems for multi-chain biologics

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515893A (en) * 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5340740A (en) * 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
FR2726003B1 (fr) * 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
PT841392E (pt) * 1996-11-12 2004-11-30 Univ Auburn Vacina viva atenuada de neospora
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020108132A1 (en) * 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
FR2832423B1 (fr) * 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
FR2836924B1 (fr) * 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
CA2491992A1 (en) * 2002-07-09 2004-01-15 Baxter International, Inc. Animal protein free media for cultivation of cells
CZ308720B6 (cs) * 2003-01-22 2021-03-24 Roche Glycart Ag Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí
FR2861080B1 (fr) * 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
JP2008505943A (ja) * 2004-07-14 2008-02-28 イゲネーオン・クレープス−イムンテラピー・フォルシュングス−ウント・エントヴィックルングス−アクチェンゲゼルシャフト グリコシル化抗体
CN101160324B (zh) * 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
JP2008539753A (ja) * 2005-05-09 2008-11-20 グリクアート バイオテクノロジー アクチェンゲゼルシャフト 修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子
ES2417147T3 (es) * 2005-10-21 2013-08-06 Revo Biologics, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso

Also Published As

Publication number Publication date
JP2010529833A (ja) 2010-09-02
US20100226912A1 (en) 2010-09-09
EP1995309A1 (en) 2008-11-26
MX2009012747A (es) 2010-02-24
AU2008252902A1 (en) 2008-11-27
EA017964B1 (ru) 2013-04-30
KR20100016540A (ko) 2010-02-12
AU2008252902B2 (en) 2013-04-04
CA2687493A1 (en) 2008-11-27
IL202213A0 (en) 2010-06-16
WO2008142124A1 (en) 2008-11-27
CN101688179A (zh) 2010-03-31
NZ580820A (en) 2012-01-12
MY159013A (en) 2016-11-30
EA200971056A1 (ru) 2010-06-30
ZA200908195B (en) 2010-07-28
EP2152855A1 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
CY1116279T1 (el) Η χρηση των ανθρωπινων κυτταρων προελευσης μυελογενους λευχαιμιας για την εκφραση αντισωματων
BRPI0821682A2 (pt) Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.
BRPI1006270A2 (pt) ''anticorpo anti a5b1, molécula de ácido nucleio isolado, célula hospedeira, método de produção de um anticorpo anti a5b1, imunoconjugado, composição farmacêutica, método de detecção de proteína a5b1, método de tratamento de um indivíduo e kit de detecção de a5b1
EP1994142A4 (en) METHOD AND COMPOSITIONS FOR FAST ISOLATION OF SMALL RNA MOLECULES
WO2007039319A3 (en) Dna microarray for rapid identification of candida albicans in blood cultures
BRPI0812772A2 (pt) Método in vitro para a identificação de moléculas antigênicas transportadas por eritrócitos e/ou anticorpos anti-eritrocitários de um indivíduo, método para combinação cruzada de eritrócitos que devem ser transfundidos em um paciente e um conjunto de reagentes para a execução do método de detecção .
IL203142A (en) Anti-cd79b antibodies, pharmaceutical compositions comprising them, use thereof and method of preparing same
BRPI0919377A2 (pt) anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
WO2006122312A3 (en) Methods of testing using a microfluidic cassette
WO2009121032A3 (en) Sample preparation devices and methods for processing analytes
WO2007065025A3 (en) Method of dna analysis using micro/nanochannel
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
BRPI0818437A2 (pt) Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
BRPI0717633A2 (pt) Anticorpo, composição farmacêutica, e, métodos para detectar uma célula expressando cxcr7 em uma amostra biológica, para tratar, prevenir ou melhorar uma doença e para identificar um modulador de cxcr7
HUE044756T2 (hu) HER-3 elleni antitestek és alkalmazásuk
KR101528970B9 (ko) 항체의 농축 방법 및 이의 치료용 생성물
EP2143043A4 (en) SYSTEM AND METHOD FOR THE AUTOMATED ANALYSIS OF CELLULAR ASSAYS AND TISSUE
WO2009025475A3 (en) The methods for detecting molecular interactions
EP1772823A4 (en) SEARCH AND SEARCH METHOD
EP1970704A4 (en) REAGENT AND METHOD FOR AGGREGATION MEASUREMENT
BRPI1005176A2 (pt) ensaio de insulina, reagente de ensaio de insulina, anticorpo monoclonal, e, método de triar anticorpos monoclonais.
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
WO2008012650A3 (en) An immunochromatography device for the diagnosis of diseases in a sample
WO2011127001A3 (en) Quantum dot-based optical sensors for rapid detection and quantitative analysis of biomolecules and biological materials
BRPI0810827A2 (pt) Moléculas de anticorpo e ácidos nucleicos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/00 (2006.01)

B350 Update of information on the portal [chapter 15.35 patent gazette]